Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > INDP Indaptus Therapeutics > Company Executives
INDP Indaptus Therapeutics
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Jeffrey A. MecklerChief Executive Officer and Director1.41M----56male08/04/2022
Mr. Walt A. Linscott, Esq.Chief Business Officer1.09M----62male08/04/2022
Mr. Nir SassiChief Financial Officer, Secretary and Treasurer------46male08/04/2022
Dr. Michael J. NewmanChief Scientific Officer and Director751.86K----67male08/04/2022
Dr. Boyan Litchev, M.D.Chief Medical Officer------56male08/04/2022
Dr. Roger J. Pomerantz, F.A.C.P.,M.D.Chairman of the Board231.71K----65male08/04/2022
Mr. William B. HayesIndependent Director118.83K----57male08/04/2022
Ms. Hila KarahIndependent Director118.78K----54female08/04/2022
Mr. Anthony J. MaddalunaIndependent Director113.99K----70male08/04/2022
Mr. Brian O’CallaghanIndependent Director80.15K----53male08/04/2022
Dr. Mark J. Gilbert, M.D.Independent Director11.24K----62male08/04/2022
Company Overview More
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
CEO: Meckler, Jeffrey A.
Market: NASDAQ
Futu Hot List
SymbolLatest price%Chg


Back to the Top